Accuracy of sonographically guided 14-gauge core-needle biopsy: Results of 715 consecutive breast biopsies with at least two-year follow-up of benign lesions

Crystal, Pavel; Koretz, Michael; Shcharynsky, Semyon; Макаров, В. В.; Strano, Selwyn

doi:10.1002/jcu.20089

Cited by 106 publications

(79 citation statements)

References 41 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The inconclusive rate of 9.2% falls in line with two large series reporting inconclusive rates of 4.3% and 7% [4,3], and the review by Willems et al describing a 1% inconclusive rate [8]. Sensitivity of 96.9% is similar to the 93% and 96% found by the two series [4,3]. Specificity of 99.4% is also similar to the 88% and 100% they describe [4,3].…”

Section: Comparison With Other Techniquessupporting

confidence: 74%

One-day core needle biopsy in a breast clinic: 4 years experience

Bulte

Polman

Schlooz-Vries

et al. 2012

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Section: Comparison With Other Techniquessupporting

confidence: 74%

One-day core needle biopsy in a breast clinic: 4 years experience

Bulte

Polman

Schlooz-Vries

et al. 2012

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…The underestimation rates of ADH and DCIS have been reported to be 6.25-65% and 16.1-66.7% at variable gauges US-guided biopsy or stereotactic biopsy (Table 4). And underestimations range from 23.1 to 65% for ADH and from 29 to 66.7% for DCIS diagnosed using US-guided 14-gauge CNB have been stated previously (Crystal et al, 2005;Jang et al, 2008;Youk at al., 2008;Chae et al, 2009).…”

Section: Discussionsupporting

confidence: 54%

“…Previous studies have suggested underestimation rates ranging from 6.25% to 65% for ADH and the underestimation rates of DCIS were from 16% to 66% by using various guiding methods including CNB or breast biopsy with vacuum assisted device (Crystal et al, 2005;Jang et al, 2008;Suh et al, 2012;Lee et al, 2013). There has been several studies about correlation with underestimation rate and clinical condition or radiologic findings such as Breast US or mammogram.…”

Section: Introductionmentioning

confidence: 99%

US-guided 14G Core Needle Biopsy: Comparison Between Underestimated and Correctly Diagnosed Breast Cancers

Kim

Youk²,

Kim³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The purpose of study was to evaluate radiologic or clinical features of breast cancer undergoing ultrasound (US)-guided 14G core needle biopsy (CNB) and analyze the differences between underestimated and accurately diagnosed groups. Materials and Methods: Of 1,898 cases of US-guided 14G CNB in our institute, 233 cases were proven to be cancer by surgical pathology. The pathologic results from CNB were invasive ductal carcinoma (IDC) (n=157), ductal carcinoma in situ (DCIS) (n=40), high-risk lesions in 22 cases, and benign in 14 cases. Among high-risk lesions, 7 cases of atypical ductal hyperplasia (ADH) were reported as cancer and 11 cases of DCIS were proven IDC in surgical pathology. Some 29 DCIS cases and 157 cases of IDC were correctly diagnosed with CNB. The clinical and imaging features between underestimated and accurately diagnosed breast cancers were compared. Results: Of 233 cancer cases, underestimation occurred in 18 lesions (7.7%). Among underestimated cancers, CNB proven ADH (n=2) and DCIS (n=11) were diagnosed as IDC and CNB proven ADH (n=5) were diagnosed at DCIS finally. Among the 186 accurately diagnosed group, the CNB results were IDC (n=157) and DCIS (n=29). Comparison of underestimated and accurately diagnosed groups for BI-RADS category, margin of mass on mammography and US and orientation of lesion on US revealed statistically significant differences. Conclusions: Underestimation of US-guided 14G CNB occurred in 7.7% of breast cancers. Between underestimated and correctly diagnosed groups, BI-RADS category, margin of the mass on mammography and margin and orientation of the lesions on US were different.

show abstract

“…However, there are certain limitations to the Ki-67 index, including standardization of a measurement method, reproducibility of measurement results, and establishment of cut-off values [13][14][15][16]. The core needle biopsy (CNB) procedure is almost as accurate as immunohistochemical analysis of surgical specimens for breast cancer diagnosis and is now widely accepted as the standard diagnostic procedure [17][18][19][20]. However, previous reports have shown variations in Ki-67 expression among pretreatment CNB specimens and post-treatment surgical specimens [21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Standardized Assessment of Ki-67 in Breast Cancer Patients Using Virtual Slides and an Automated Analyzer in Comparison to Central/Local Pathological Assessments

Mizuno¹,

Fuchikami²,

Natori³

et al. 2014

JCT

View full text Add to dashboard Cite

Purpose: To standardize the methods to measure Ki-67, there is an interest in automating the assessment of Ki-67. Therefore, we reviewed the possibility of introducing an automated analyzer to standardize the Ki-67 evaluation method. Methods: We retrospectively reviewed a clinical database of patients who underwent surgery for early breast cancer at Tokyo-West Tokushukai Hospital. Among them, those who underwent preoperative core needle biopsy (CNB) were enrolled. The concordance rates of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and Ki-67 by local pathologists were reviewed (valuations made by local pathologists), and nonmatching cases (from August 2008 to October 2011) were reassessed both by central review and using an automated analyzer with virtual slides. The results were compared with the evaluations made by local pathologists, and we reexamined the concordance rate by using central review and the automated analyzer. Results: The concordance rate of Ki-67 evaluations made by local pathologists in the preoperative CNB and surgical specimens was 78.7% in 287 cases pathologically assessed from October 2008 to March 2013. This rate was significantly lower (p < 0.01) than that of ER (95.6%), PgR (88.5%), and HER2 (91.6%). Reassessment of the 37 cases of nonmatching Ki-67 values from 2008 to October 2011 using central review and an automated analyzer resulted in clear improvement in matching of 22 (92.1%) and 24 (93.1%) of 37 cases, respectively. Conclusion: The concordance rate of Ki-67 in preoperative CNB and surgical specimens was lower than that of other biological markers; however, they were nearly equal by reassessment using central review and an automated analyzer.

show abstract

Accuracy of sonographically guided 14-gauge core-needle biopsy: Results of 715 consecutive breast biopsies with at least two-year follow-up of benign lesions

Abstract: Sonographically guided 14-gauge CNB is a safe and accurate method for evaluating breast lesions that require tissue sampling. Radiologic-pathologic correlation and follow-up of benign lesions are essential for a successful breast biopsy program.

Cited by 106 publications

References 41 publications

One-day core needle biopsy in a breast clinic: 4 years experience

One-day core needle biopsy in a breast clinic: 4 years experience

US-guided 14G Core Needle Biopsy: Comparison Between Underestimated and Correctly Diagnosed Breast Cancers

Standardized Assessment of Ki-67 in Breast Cancer Patients Using Virtual Slides and an Automated Analyzer in Comparison to Central/Local Pathological Assessments

Contact Info

Product

Resources

About